

---

## News from Cyclo Therapeutics:

### Cyclo Therapeutics Expands Research in Alzheimer's Disease

Earlier this month, Cyclo Therapeutics announced it has initiated a Phase 2b study of its investigational therapy, Trappsol® Cyclo™ for the treatment of early Alzheimer's disease (AD). This work expands the study of Trappsol Cyclo, which is currently being investigated in the [global Phase 3 study for Niemann-Pick Type C known as TransportNPC™](#). Dr. Lise Kjems, Chief Medical Officer for Cyclo said, "The expansion of Trappsol Cyclo research in Alzheimer's disease is an important step forward, as this is a very large, underserved disease community living with significant neurocognitive manifestations of their disease. Based upon our experience in both NPC and Alzheimer's disease, we believe there is great potential to improve the lives of people living with both of these diseases."

Dr. Martin Farlow, Professor of Neurology and Vice-Chairman of Research in the Department of Neurology at the Indiana University School of Medicine in Indianapolis, Associate Co-Director of the Indiana Alzheimer's Disease Center in Indianapolis, and Director for the IU Center for Alzheimer's Disease and Related Diseases at Indiana University Hospital commented, as the global Principal Investigator for Cyclo Therapeutics' Phase 2b clinical trial in patients with Early Alzheimer's Disease, commented, "I am very excited to see this study getting initiated. Cyclo Therapeutics' Trappsol® Cyclo™ investigational drug shows promise in AD, based on the drug's ability to stabilize disease progression in an AD patient. Notably, the ability of Trappsol® Cyclo™ to gain access to the CSF/brain and impact CSF tau and serum 24S-hydroxycholesterol when intravenously administered are most impressive and represent an exciting avenue for therapeutic development. As you know, the field of AD is actively searching for novel therapeutic approaches and Cyclo Therapeutics' Trappsol® Cyclo™ is at the forefront of alternative disease-modifying therapeutics. I look forward to working with the Cyclo Therapeutics team on this important study with a trial design that will provide critical data and insights in developing this therapy."

---